10x Genomics (TXG) Liabilities and Shareholders Equity (2018 - 2026)

10x Genomics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 12.44% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.1 billion (up 10.16% YoY), while the FY2025 annual figure was $1.0 billion, up 13.36% from the prior year.
• Liabilities and Shareholders Equity came in at $1.0 billion for Q1 2026 at 10x Genomics, down from $1.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $903.4 million in Q1 2025.
• A 5-year average of $977.9 million and a median of $989.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity retreated 8.99% in 2024 and climbed 13.36% in 2025, its largest moves.
• 10x Genomics' Liabilities and Shareholders Equity stood at $1.0 billion in 2022, then dropped by 6.2% to $965.1 million in 2023, then slipped by 4.82% to $918.6 million in 2024, then gained by 13.36% to $1.0 billion in 2025, then dropped by 2.46% to $1.0 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.0 billion, $1.0 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison